Of technical interest, INSM fell to its bullish channel's midline level drawn last APR 09 - This is not a dead stock, since it contains several investigational drugs in its pipeline, but recent news regarding its most awaited drug (ALS recomb DNA modulator I believe - not strong or interested in fundies myself), failed to please the institutional investors and the public at-large: